Schisandrin B prevents ulcerative colitis and colitis-associated-cancer by activating focal adhesion kinase and influence on gut microbiota in an in vivo and in vitro model - Li, Jiani; Lu, Yuan; Wang, Duowei; Quan, Fei; Chen, Xin; Sun, Rui; Zhao, Sen; Yang, Zhisen; Tao, Weiyan; Ding, Dong; Gao, Xinghua; Cao, Qiuhua; et al. (European journal of pharmacology, 2019)
Keywords: Animals; Caco-2 Cells; Colitis, Ulcerative - complications; Colitis, Ulcerative - microbiology; Colitis, Ulcerative - pathology; Colitis, Ulcerative - prevention & control; Colitis-associated cancer (CAC); Colonic Neoplasms - complications; Colonic Neoplasms - pathology; Cyclooctanes - pharmacology; Cytoprotection - drug effects; Enzyme Activation - drug effects; Focal adhesion kinase (FAK); Focal Adhesion Protein-Tyrosine Kinases - metabolism; Gastrointestinal Microbiome - drug effects; Gut microbiota; HCT116 Cells; Humans; Intestinal Mucosa - drug effects; Intestinal Mucosa - metabolism; Lignans - pharmacology; Male; Mice; Mice, Inbred C57BL; Permeability - drug effects; Polycyclic Compounds - pharmacology; Schisandrin B (SchB); Signal Transduction - drug effects; Ulcerative colitis (UC); Gut microbiota; Ulcerative colitis (UC); Schisandrin B (SchB); Focal adhesion kinase (FAK); Colitis-associated cancer (CAC)